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Introduction {#path5392-sec-0001}
============

Atherosclerosis is a lipid‐driven inflammatory disease characterised by plaque formation in the large arteries. These fatty plaques contain lipid‐laden macrophages that accumulate because of the recruitment of circulating monocytes and local differentiation and proliferation of macrophages [1](#path5392-bib-0001){ref-type="ref"}, [2](#path5392-bib-0002){ref-type="ref"}, [3](#path5392-bib-0003){ref-type="ref"}, [4](#path5392-bib-0004){ref-type="ref"}. Atherosclerosis is initiated by endothelial damage induced by classical risk factors such as high cholesterol, high blood pressure, obesity, diabetes, smoking and low shear stress [5](#path5392-bib-0005){ref-type="ref"}, [6](#path5392-bib-0006){ref-type="ref"}, [7](#path5392-bib-0007){ref-type="ref"}, [8](#path5392-bib-0008){ref-type="ref"}, [9](#path5392-bib-0009){ref-type="ref"}, leading to local subendothelial accumulation of low‐density lipoproteins (LDL), which are prone to oxidative modifications. Such modified lipoprotein particles trigger inflammatory responses inducing monocyte attraction. These monocytes subsequently differentiate into macrophages that scavenge oxidised LDL and eventually become foam cells. In atherogenesis, macrophages secrete numerous pro‐ but also anti‐inflammatory mediators, pro‐thrombotic tissue factor and enzymes such as matrix‐degrading proteases, all of which influence plaque growth, cellular composition and stability. Although early lesions are dominated by plaque foam cells, plaque foam cell content decreases with atherosclerosis progression towards more advanced and fibrotic lesions or by induction of regression, such as mediated by cholesterol lowering [10](#path5392-bib-0010){ref-type="ref"}, [11](#path5392-bib-0011){ref-type="ref"}, [12](#path5392-bib-0012){ref-type="ref"}. Excessive LDL uptake induces macrophage apoptosis [13](#path5392-bib-0013){ref-type="ref"} and these apoptotic cells can be sensed by other macrophages via 'find‐me' and 'eat‐me' signals and are cleared through a process called efferocytosis [14](#path5392-bib-0014){ref-type="ref"}. When plaques become more advanced, the number of apoptotic cells increases and macrophage efferocytosis becomes limited, causing secondary necrosis, leading to the formation of a necrotic core [15](#path5392-bib-0015){ref-type="ref"}, [16](#path5392-bib-0016){ref-type="ref"}. Because of their complex and broad range of functions, macrophages are central in the formation, maintenance and rupture, and therefore clinical complications, of the atherosclerotic plaque.

Around the year 2000, the macrophage phenotype range was initially divided into two extremes of the activation spectrum, namely pro‐inflammatory M1 macrophages and anti‐inflammatory M2 macrophages [17](#path5392-bib-0017){ref-type="ref"}, [18](#path5392-bib-0018){ref-type="ref"}, [19](#path5392-bib-0019){ref-type="ref"}. However, it has now become established by numerous more recent studies that the macrophage phenotype spectrum is much broader, containing a continuum of phenotypes induced by local tissue cues [20](#path5392-bib-0020){ref-type="ref"}, [21](#path5392-bib-0021){ref-type="ref"}, [22](#path5392-bib-0022){ref-type="ref"}. The atherosclerotic microenvironment is diverse and drives a range of macrophage phenotypes. Histological studies previously showed the presence of M1 and M2 macrophage subsets and their spatial localisation in atherosclerotic lesions [23](#path5392-bib-0023){ref-type="ref"}, [24](#path5392-bib-0024){ref-type="ref"}, [25](#path5392-bib-0025){ref-type="ref"}, [26](#path5392-bib-0026){ref-type="ref"}. Stöger *et al* [23](#path5392-bib-0023){ref-type="ref"} described that M1 macrophages are the predominant population in rupture‐prone shoulder regions of the plaque. The plaque adventitia enclosed a pronounced M2 macrophage phenotype, whereas no significant differences in macrophage populations were seen in the fibrous cap. These studies highlighted the critical importance of macrophage polarisation regarding atherogenesis.

The discovery and rapid progress of single‐cell RNA sequencing (scRNAseq) and tools exploiting large combinations of protein labelling of cells, such as cytometry by time of flight (CyTOF), have now enabled more detailed transcriptional and high‐dimensional protein analysis of the cell types present in atherosclerotic plaques. Specific subsets of cells can now be distinguished based on overlapping or differing transcriptomes or protein marker sets. Using these tools, it has become possible to discriminate tissue macrophage subsets and characterise their functions. In recent years, scRNAseq and CyTOF were applied to mouse and human atherosclerosis, which has given novel insights regarding immune cell function and the composition of atherosclerotic plaques [27](#path5392-bib-0027){ref-type="ref"}, [28](#path5392-bib-0028){ref-type="ref"}, [29](#path5392-bib-0029){ref-type="ref"}, [30](#path5392-bib-0030){ref-type="ref"}, [31](#path5392-bib-0031){ref-type="ref"}, [32](#path5392-bib-0032){ref-type="ref"}, [33](#path5392-bib-0033){ref-type="ref"}. In this review we will discuss recent progress investigating macrophage subsets by applying novel technologies in atherosclerotic disease in mice and men.

Mouse atherosclerotic macrophages {#path5392-sec-0002}
=================================

Several studies have now investigated macrophages in murine atherosclerosis by either CyTOF or scRNAseq approaches (see supplementary material, Table [S1](#path5392-supitem-0001){ref-type="supplementary-material"}) [27](#path5392-bib-0027){ref-type="ref"}, [28](#path5392-bib-0028){ref-type="ref"}, [29](#path5392-bib-0029){ref-type="ref"}, [30](#path5392-bib-0030){ref-type="ref"}, [31](#path5392-bib-0031){ref-type="ref"}, [32](#path5392-bib-0032){ref-type="ref"}, [34](#path5392-bib-0034){ref-type="ref"}. These investigated *Ldlr* ^−/−^ or apolipoprotein E (*Apoe)* ^−/−^ mouse models, either on chow or on a Western (high‐fat) diet to accelerate atherogenesis. Most of the studies showed that macrophages are the most dominant immune cell type within the atherosclerotic plaque [28](#path5392-bib-0028){ref-type="ref"}, [30](#path5392-bib-0030){ref-type="ref"}, [35](#path5392-bib-0035){ref-type="ref"}. The total macrophage population proportion was further increased in mice with advanced atherosclerosis [28](#path5392-bib-0028){ref-type="ref"}. Generally speaking, three main subtypes of macrophage could be identified, involving resident‐like macrophages, pro‐inflammatory macrophages and foamy TREM2^hi^ macrophages (Figure [1](#path5392-fig-0001){ref-type="fig"}). Future additional differentiation of macrophage subsets can probably be made based on technical and numerical advances. However, currently available data suggest that plaque macrophages can be subdivided into at least three main macrophage populations. Several studies identified more than three populations These are probably further subdivisions of the three main clusters. We will discuss these three macrophage subsets in mouse and human atherosclerosis below.

![Characteristics of mouse macrophages residing in the atherosclerotic aorta. Three macrophage populations (pro‐inflammatory, anti‐inflammatory foamy TREM2^hi^ and resident‐like), with each expressing specific markers and performing unique functions, reside in the atherosclerotic plaque of *Ldlr* ^*−/−*^ and *Apoe* ^*−/−*^ mice, whereas only resident‐like macrophages are found in the healthy aorta. Local., localisation.](PATH-250-705-g001){#path5392-fig-0001}

Atherosclerotic resident‐like macrophages {#path5392-sec-0003}
=========================================

Concerning their origin, macrophages found in tissues can be divided into two groups: infiltrating monocyte‐derived macrophages and embryonically derived tissue‐resident macrophages [36](#path5392-bib-0036){ref-type="ref"}, [37](#path5392-bib-0037){ref-type="ref"}, [38](#path5392-bib-0038){ref-type="ref"}. Whereas tissue‐resident macrophages reside in a specific tissue and are mainly seeded during embryonic development, infiltrating monocyte‐derived macrophages often accumulate in response to local inflammatory cues in the tissue [39](#path5392-bib-0039){ref-type="ref"}, [40](#path5392-bib-0040){ref-type="ref"}. Most of the tissues harbour resident macrophages. For example, Kupffer cells are tissue‐resident macrophages of the liver and microglia are the tissue‐resident macrophages of the brain. Tissue‐resident macrophages not only have a role in tissue homeostasis but also form the first line of defence when a pathogen invades the tissue.

Ensan *et al* [41](#path5392-bib-0041){ref-type="ref"} identified mouse resident arterial macrophages that arose embryonically from C‐X3‐C motif chemokine receptor 1 (*Cx3cr1)* ^*+*^ precursors. These resident arterial macrophages specifically expressed lymphatic vessel endothelial hyaluronan receptor 1 (*Lyve1*). Winkels *et al* [27](#path5392-bib-0027){ref-type="ref"} confirmed the expression of *Cx3cr1* and *Lyve* by resident‐like macrophages in healthy *Apoe* ^*−/−*^ mice. Depletion of LYVE1^+^ macrophages in *Lyve* ^*wt/cre*^ *Csf1r* ^*flox/flox*^ mice resulted in increased arterial stiffness and collagen deposition, suggesting a key role in these processes [42](#path5392-bib-0042){ref-type="ref"}. Kim *et al* [29](#path5392-bib-0029){ref-type="ref"} identified three macrophage subsets expressing *Lyve1* in atherosclerotic plaques of *Ldlr* ^−/−^ mice using scRNAseq. The macrophage subset expressing the highest *Lyve1* levels of all aortic CD45^+^ cells also expressed increased levels of mRNA for anti‐inflammatory markers such as mannose receptor *Mrc1* (also known as *Cd206*), transcription factor *Mafb* [43](#path5392-bib-0043){ref-type="ref"} and other genes mainly linked to the endocytosis pathway. Cochain *et al* [28](#path5392-bib-0028){ref-type="ref"} also identified a cluster of resident‐like macrophages in atherosclerotic plaques expressing *Lyve1* and other markers for resident‐like macrophages, such as factor XIIIa (*F13a1)* and growth arrest‐specific 6 (*Gas6*) [44](#path5392-bib-0044){ref-type="ref"}. The resident‐like macrophages were present in both healthy and atherosclerotic aortas [27](#path5392-bib-0027){ref-type="ref"}, [28](#path5392-bib-0028){ref-type="ref"}. However, the resident‐like macrophage subset of healthy aortas expressed higher levels of *Lyve1*, whereas the resident‐like macrophages of the atherosclerotic aortas expressed higher levels of C‐C motif chemokine receptor 2 (*Ccr2)*, which is truly a marker for recruited macrophages. This suggests that atherosclerotic aortas contain resident macrophages originating from an embryonic pool, which upon atherosclerosis development are replaced by or accompanied by recruited monocyte‐derived macrophages that adopt a resident‐like macrophage phenotype. Resident‐like macrophages in lesions further express folate receptor β (*Folr2*), carbonyl reductase 2 (*Cbr2)*, platelet factor 4 *(Pf4)*, selenoprotein P (*Sepp1)* and (as in Kim *et al* [29](#path5392-bib-0029){ref-type="ref"}) *Cd206. Folr2*, *Cbr2*, *Sepp1* and *Cd206* are all associated with M2‐like phenotype [24](#path5392-bib-0024){ref-type="ref"}, thus suggesting anti‐inflammatory characteristics of resident‐like macrophages in atherosclerosis. *Folr2* expression was increased in atherosclerotic plaques compared with normal artery walls [45](#path5392-bib-0045){ref-type="ref"}. PF4 has previously been described as a platelet‐specific molecule. However, more recent data also show PF4 expression in macrophages [46](#path5392-bib-0046){ref-type="ref"}, [47](#path5392-bib-0047){ref-type="ref"}. Macrophage PF4 (also known as CXCL4) was found to be positively correlated with clinical parameters such as lesion grade and the presence of symptomatic atherosclerotic disease in human carotid atherosclerotic plaques [46](#path5392-bib-0046){ref-type="ref"}. Pathway analysis revealed that resident‐like plaque macrophages are involved in the receptor‐mediated endocytosis [28](#path5392-bib-0028){ref-type="ref"}, which is in line with the endocytosis pathway identified by Kim *et al* [29](#path5392-bib-0029){ref-type="ref"}. Likewise, Lin *et al* [31](#path5392-bib-0031){ref-type="ref"} identified a *Cx3cr1* ^*+*^ resident‐like macrophage subset enriched for *Mrc1, Gas6, F13a1, Sepp1, Cbr2, Pf4, Lyve1* and *Folr2*. There was no difference in the population proportion of resident‐like macrophages between progressive and regressive plaques.

Cochain *et al* [28](#path5392-bib-0028){ref-type="ref"} also identified a resident‐like macrophage subset expressing *Lyve1*, *Ccl9*, *F13a1*, *Folr2* and *Sepp1* in atherosclerotic *Apoe* ^*−/−*^ mice. Cole *et al* [30](#path5392-bib-0030){ref-type="ref"} found a resident‐like macrophage population expressing CD206 and CD169 in atherosclerotic *Apoe* ^−/−^ mice using CyTOF. This supports the notion that different atherosclerotic models contain resident‐like macrophages. CD169 encodes the lectin‐like adhesion molecule SIGLEC‐1 that is expressed by certain resident‐like macrophage subpopulations [48](#path5392-bib-0048){ref-type="ref"}, [49](#path5392-bib-0049){ref-type="ref"}, [50](#path5392-bib-0050){ref-type="ref"} and it can interact with scavenger receptor SR‐BI to mediate the uptake of oxidised LDL [51](#path5392-bib-0051){ref-type="ref"}.

Furthermore, at least four studies described that resident‐like macrophages can proliferate by showing either protein expression of proliferation marker Ki‐67 or enrichment for cell cycle genes [29](#path5392-bib-0029){ref-type="ref"}, [31](#path5392-bib-0031){ref-type="ref"}, [39](#path5392-bib-0039){ref-type="ref"}, [52](#path5392-bib-0052){ref-type="ref"}. This confirms a previous study showing that the lesional microenvironment orchestrates macrophage proliferation in atherosclerosis [53](#path5392-bib-0053){ref-type="ref"}.

McArdle *et al* [34](#path5392-bib-0034){ref-type="ref"} recently used atherosclerotic *Apoe* ^*−/−*^ *Cx3cr1* ^*GFP*^ *CD11c* ^*YFP*^ mice in which four macrophage subsets were identifiable by GFP, YFP, a double‐positive and a double‐negative signal. Bulk RNAseq data of these four flow‐sorted macrophage subsets were compared with representative genes of each macrophage subset found by Cochain *et al* [28](#path5392-bib-0028){ref-type="ref"}, Kim *et al* [29](#path5392-bib-0029){ref-type="ref"} and Lin *et al* [31](#path5392-bib-0031){ref-type="ref"} and revealed that three main macrophage populations: resident‐like, inflammatory and TREM2^hi^ macrophages were overlapping with one of the subsets of the study of McArdle *et al* [34](#path5392-bib-0034){ref-type="ref"}. However, the fourth population (double‐negative) of McArdle *et al* [34](#path5392-bib-0034){ref-type="ref"} did not overlap with a macrophage subset from the other studies. These resident‐like macrophages again showed enrichment for *Sepp1*, *Txnip* and *Pf4* and live‐cell microscopy showed that these cells migrate less compared with other macrophage subsets and their shape resembles that of dendritic cells.

Immunostaining studies further showed that resident‐like macrophages are predominantly present in the adventitia, both in the healthy blood vessel [41](#path5392-bib-0041){ref-type="ref"} and in the atherosclerotic aorta, where their number is increased compared with healthy settings [52](#path5392-bib-0052){ref-type="ref"}.

In summary, various single‐cell studies identified resident‐like macrophages within the adventitia of the healthy and atherosclerotic aorta of *Ldlr* ^−/−^ and *Apoe* ^−/−^ mice. Different studies reported that resident‐like macrophages proliferate, play a role in endocytosis and are enriched for genes such as *Lyve1*, *Cx3cr1*, *Folr2*, *Cd206*, *F13a1*, *Cbr2*, *Sepp1* and *Pf4* expression, which resembles an M2‐like phenotype.

Atherosclerotic inflammatory macrophages {#path5392-sec-0004}
========================================

In atherosclerosis, the increased number of circulating monocytes infiltrate the arterial wall using different chemokine--chemokine receptor dyads, followed by support of the endothelial adhesion molecules [54](#path5392-bib-0054){ref-type="ref"}, [55](#path5392-bib-0055){ref-type="ref"}, [56](#path5392-bib-0056){ref-type="ref"}. In the intima, infiltrated monocytes can differentiate into macrophages. Inflammatory macrophages upon activation will express surface markers, including major histocompatibility complex class II, Fc receptor CD64 and costimulatory molecules CD80 and CD86, and will release IL‐6, TNF and IL‐23, and express nitric oxide synthase 2. Inflammatory macrophages are essential for the phagocytosis and intra‐ and extracellular killing of bacterial, fungal and viral infections [57](#path5392-bib-0057){ref-type="ref"}, [58](#path5392-bib-0058){ref-type="ref"}, [59](#path5392-bib-0059){ref-type="ref"}. However, chronic macrophage activation will lead to tissue injury, matrix degradation and impaired wound healing.

Different single‐cell studies have described the presence and phenotype of inflammatory macrophages in the atherosclerotic aorta [27](#path5392-bib-0027){ref-type="ref"}, [28](#path5392-bib-0028){ref-type="ref"}, [29](#path5392-bib-0029){ref-type="ref"}, [31](#path5392-bib-0031){ref-type="ref"}, [34](#path5392-bib-0034){ref-type="ref"}. Cochain *et al* [28](#path5392-bib-0028){ref-type="ref"} showed that these inflammatory macrophages are enriched for numerous classical pro‐inflammatory transcripts such as *Cxcl2*, *Ccl3*, *Ccl4*, *Il1α*, *Il1β, Tlr2, Tnf*, nucleotide‐binding oligomerisation domain, leucine‐rich repeat and pyrin domain containing 3 (*Nlrp3)* and specific transcription factors such as CCAAT enhancer‐binding protein beta (*Cebpb)* [60](#path5392-bib-0060){ref-type="ref"} and early growth response 1 (*Egr1)* [61](#path5392-bib-0061){ref-type="ref"} *. Il1α*, *Il1β*, and *Nlrp3* are important in regulating atherosclerosis progression [62](#path5392-bib-0062){ref-type="ref"}, [63](#path5392-bib-0063){ref-type="ref"}, [64](#path5392-bib-0064){ref-type="ref"}. As a result of macrophage activation, negative feedback mechanisms are activated that partially compensate for the pro‐inflammatory and pro‐atherogenic effect and stimulate cell survival [65](#path5392-bib-0065){ref-type="ref"}. Cochain *et al* [28](#path5392-bib-0028){ref-type="ref"} found enrichment of negative feedback NF‐κB inhibitors (*Nfkbia, Nfkbid* and *Nfkbiz)*, nuclear receptor subfamily 4 group A member 1 (*Nr4a1)*, immediate early response 3 (*Ier3)* and the mRNA‐binding protein *Zpf36*. *Nr4a1* and *Zpf36* have both been shown to inhibit the inflammatory macrophage phenotype in atherosclerosis [66](#path5392-bib-0066){ref-type="ref"}, [67](#path5392-bib-0067){ref-type="ref"}. The inflammatory response was the most significantly enriched pathway among the inflammatory macrophages. Lin *et al* [31](#path5392-bib-0031){ref-type="ref"} showed that inflammatory plaque macrophages were enriched for the expression of different chemokines (*Ccl2‐5, Cxcl1, Cxcl2, Cxcl10), Nlrp3, Tnf* and type I interferons signalling genes such as *Ifitm3*, *Irf7*, *Isg15* and *Mnda*. Importantly, it has been shown that type I interferons are generally pro‐atherogenic [68](#path5392-bib-0068){ref-type="ref"}, [69](#path5392-bib-0069){ref-type="ref"}. The relative frequency of the inflammatory macrophage subset increased with a Western‐type diet compared with chow feeding, confirming the positive association with plaque progression.

Kim *et al* [29](#path5392-bib-0029){ref-type="ref"} investigated the association of macrophage foam cell phenotype with their inflammatory characteristics and showed that inflammatory plaque macrophages are particularly non‐foamy. Many inflammatory transcripts, including *Il1β*, *Nlrp3*, *Nfkbia*, *Tlr2* and *Tnf*, were upregulated in these non‐foamy inflammatory macrophages. Inflammatory pathways (TLR and TNF signalling, cytokine--chemokine interaction and NF‐κB signalling pathways) were confirmed to be dominant in non‐foamy inflammatory macrophage function in plaques.

McArdle *et al* [34](#path5392-bib-0034){ref-type="ref"} also found that inflammatory plaque macrophages were enriched for the expression of *Nlrp3, Tnf* and *Ccl3*. Intravital imaging identified that inflammatory macrophages have elongations, are dendritic‐shaped and migrated significantly more compared with resident‐like macrophages.

Different single‐cell studies have described that inflammatory macrophages are only present in the atherosclerotic aorta [27](#path5392-bib-0027){ref-type="ref"}, [28](#path5392-bib-0028){ref-type="ref"} where they represent the largest (about half) macrophage subset [28](#path5392-bib-0028){ref-type="ref"}, [29](#path5392-bib-0029){ref-type="ref"}. This was confirmed in both atherosclerotic *Ldlr* ^−/−^ and *Apoe* ^−/−^ mice. Stöger *et al* [23](#path5392-bib-0023){ref-type="ref"} observed in human patient material that inflammatory macrophages were the predominant population of the plaque shoulder regions, which is comparable with the finding of Kim *et al* [29](#path5392-bib-0029){ref-type="ref"}, who found that inflammatory macrophages reside in the intima, which includes the plaque shoulder regions.

Overall, inflammatory macrophages form the major macrophage population within the intima of the plaque, are mainly non‐foamy cells that are exclusively present in the atherosclerotic aorta and accordingly can be considered the main drivers of lesional inflammation. These inflammatory macrophages typically express inflammatory pathways and markers, including *Tnf*, *Nlrp3*, *Il1β*, *Egr1*, *Zpf36*, *Ier3, Cepbp*, *Cxcl2* and *Ccl2‐5*, and are therefore associated with an M1‐like phenotype.

Atherosclerotic TREM2^hi^ macrophages {#path5392-sec-0005}
=====================================

TREM2 is a myeloid‐specific transmembrane glycoprotein that can interact with APOE, APOJ, anionic ligands, glycerophospholipids and sphingomyelins [70](#path5392-bib-0070){ref-type="ref"}, [71](#path5392-bib-0071){ref-type="ref"}, [72](#path5392-bib-0072){ref-type="ref"}, [73](#path5392-bib-0073){ref-type="ref"}, [74](#path5392-bib-0074){ref-type="ref"}, [75](#path5392-bib-0075){ref-type="ref"}. Furthermore, TREM2 is expressed on anti‐inflammatory macrophages and has been shown to limit macrophage activation [76](#path5392-bib-0076){ref-type="ref"}. Macrophage TREM2 protects against infections, adipocyte hypertrophy, systemic hypercholesterolemia, body fat accumulation and glucose intolerance in mice [77](#path5392-bib-0077){ref-type="ref"}, [78](#path5392-bib-0078){ref-type="ref"} and has been shown to negatively correlate with human plaque stability [79](#path5392-bib-0079){ref-type="ref"}.

Cochain *et al* [28](#path5392-bib-0028){ref-type="ref"} detected TREM2^hi^ macrophages exclusively in the plaque and not in the healthy aorta. TREM2^hi^ macrophages expressed increased levels of *Trem2*, *Cd9*, secreted phosphoprotein 1 (*Spp1)*, hydrogen voltage‐gated channel 1 (*Hvcn1)* and several cathepsins (*Ctsb*, *Ctsd* and *Ctsz*). Cathepsins are lysosomal proteolytic enzymes of macrophages that promote atherosclerotic inflammation and plaque vulnerability [80](#path5392-bib-0080){ref-type="ref"}, [81](#path5392-bib-0081){ref-type="ref"}, [82](#path5392-bib-0082){ref-type="ref"}. For example, cathepsin Z stimulates the production of pro‐inflammatory cytokines and cathepsin D controls multiple aspects of apoptosis and modifies LDL to promote LDL engulfment by macrophages and subsequent foam cell formation. Cathepsin B has been shown to mediate the degradation of the extracellular matrix. Pathway analysis of lesional TREM2^hi^ macrophages showed enrichment in lipid metabolism, regulation of cholesterol efflux, oxidative stress and catabolism, suggesting a link with intracellular lipid accumulation and foam cell formation.

TREM2^hi^ macrophages were present in mice with both early and advanced atherosclerotic lesions and found in both *Ldlr* ^*−/−*^ and *Apoe* ^−/−^ atherosclerotic mice [28](#path5392-bib-0028){ref-type="ref"}. Moreover, TREM2^hi^ macrophages were detected during both the progression and the regression of atherosclerosis [31](#path5392-bib-0031){ref-type="ref"}. Lin *et al* [31](#path5392-bib-0031){ref-type="ref"} showed that TREM2^hi^ macrophages were enriched for the expression of *Trem2*, *Cd9*, *Ctsb*, galectin‐3 (*Lgals3*), *Spp1* and aldolase (*Aldoa)*, of which CD9 expression was confirmed by flow cytometry. Tetraspanin CD9 is an exosome and anti‐inflammatory marker of monocytes and macrophages and is associated with CD36 expression, which triggers foam cell formation in response to oxidised LDL exposure [83](#path5392-bib-0083){ref-type="ref"}, [84](#path5392-bib-0084){ref-type="ref"}. Kim *et al* [29](#path5392-bib-0029){ref-type="ref"} showed that TREM2^hi^ macrophages are indeed lipid‐laden foam cells with increased expression of *Trem2*, *Lgals3*, ATP binding cassette subfamily G member 1 (*Abcg1), Abca1*, *Ctsb*, *Fabp4*, *Mertk* and *Cd36*. Galectin‐3 expression drives the differentiation of monocytes to macrophages and has been associated with alternative macrophage activation and plaque progression [85](#path5392-bib-0085){ref-type="ref"}, [86](#path5392-bib-0086){ref-type="ref"}, [87](#path5392-bib-0087){ref-type="ref"}. *Fabp4* has been previously described as a transcriptional marker of foamy macrophages in atherosclerotic *Apoe* ^*−/−*^ mice [29](#path5392-bib-0029){ref-type="ref"}. Pathways analysis by Kim *et al* [29](#path5392-bib-0029){ref-type="ref"} showed enrichment of oxidative phosphorylation, lysosome, cholesterol metabolism and peroxisome proliferator‐activated receptors signalling pathways in these foamy TREM2^hi^ macrophages, again confirming the association of the foamy phenotype with metabolic pathways. Gene expression of foamy macrophages was also associated with plaque‐resolving parameters such as efferocytosis and tissue repair compared with that of non‐foamy inflammatory macrophages.

McArdle *et al* [34](#path5392-bib-0034){ref-type="ref"} showed that TREM2^hi^ macrophages were also enriched for *Cd9*, *Trem2*, *Ctsd* and *Spp1*. Live‐cell imaging identified TREM2^hi^ macrophages to exist in a more rounded shape and to migrate significantly more compared with the resident‐like macrophages.

Cochain *et al* [28](#path5392-bib-0028){ref-type="ref"} detected TREM2^hi^ macrophages exclusively in the plaque and not in the healthy aorta. Foamy macrophages predominantly reside in the intima where they have taken up atherogenic lipoproteins and subsequently form a lipid‐rich core that can progress to become a necrotic core [1](#path5392-bib-0001){ref-type="ref"}.

In summary, TREM2^hi^ macrophages are foamy lipid‐laden macrophages accumulating in the plaque intima and its necrotic core and not in the healthy aorta. Pathway enrichment analysis confirmed the role of TREM2^hi^ macrophages in cholesterol metabolism and oxidative phosphorylation, which was already suggested by the foamy feature of the TREM2^hi^ macrophages. *Trem2*, *Cd9*, *Spp1*, *Lgals3* and *Ctsb* are markers of TREM2^hi^ macrophages, as found by different studies. TREM2^hi^ macrophages seem to have an M2‐like phenotype.

Smooth muscle cell transdifferentiation {#path5392-sec-0006}
=======================================

Several studies have described that smooth muscle cells (SMCs) can also become foam cells after lipid loading [88](#path5392-bib-0088){ref-type="ref"}, [89](#path5392-bib-0089){ref-type="ref"}, [90](#path5392-bib-0090){ref-type="ref"}, [91](#path5392-bib-0091){ref-type="ref"}. Upon foam cell formation, SMCs express lower levels of typical SMC markers (α‐SM actin and α‐tropomyosin) and increased levels of macrophage markers such as CD68, galectin 3 and the macrophage foam cell marker ABCA1 [89](#path5392-bib-0089){ref-type="ref"}. It has been described that these transdifferentiated foam cells may make up a major component of advanced plaques. Co‐staining with CD68 and α‐SM actin of human coronary artery sections suggested that 40% of CD68^+^ cells originated from SMCs in advanced human coronary atherosclerosis [90](#path5392-bib-0090){ref-type="ref"}. Also, Kim *et al* [29](#path5392-bib-0029){ref-type="ref"} reported that a foam cell subset expressed SMC markers (α‐SM actin and SM22α) and showed the absence of CD45 in murine atherosclerosis. However, Wirka *et al* [32](#path5392-bib-0032){ref-type="ref"} analysed the single‐cell transcriptional profile of SMC‐specific lineage‐traced mouse plaque cells together with scRNAseq data of human atherosclerotic plaques, which raised the suggestion that both mouse and human SMCs transdifferentiate into fibroblast‐like cells and do not acquire macrophage characteristics [31](#path5392-bib-0031){ref-type="ref"}. They confirmed this suggestion using multiple protein‐based assays. Although experimental data clearly showed SMC conversion into cells with macrophage characteristics, the actual contribution of transdifferentiation from SMCs to macrophages (or potentially vice versa) to the human atherosclerotic process and subsequent clinical complications still need to be substantiated.

Human atherosclerotic plaque macrophage subsets {#path5392-sec-0007}
===============================================

Recently, the first publications applying single‐cell technologies on human atherosclerotic plaques were released [27](#path5392-bib-0027){ref-type="ref"}, [32](#path5392-bib-0032){ref-type="ref"}, [33](#path5392-bib-0033){ref-type="ref"}. Although Wirka *et al* [32](#path5392-bib-0032){ref-type="ref"} described one macrophage subset in atherosclerotic coronary arteries, Fernandez *et al* [33](#path5392-bib-0033){ref-type="ref"} and Winkels *et al* [27](#path5392-bib-0027){ref-type="ref"} identified more macrophage subpopulations residing in carotid artery plaques. Using CyTOF, Winkels *et al* [27](#path5392-bib-0027){ref-type="ref"} detected two potential macrophage subsets, a CD11b^+^HLA‐DR^med^ and a CD11b^+^CD36^+^ population. Fernandez *et al* [33](#path5392-bib-0033){ref-type="ref"} found CD206^hi^CD163^hi^ and CD206^lo^CD163^lo^ macrophages using mass cytometry. The CD206^hi^CD163^hi^ macrophage subset may be similar to the phenotype of the resident‐like macrophage subset described in murine atherosclerosis based on CD206 expression and the fact that haemoglobin--haptoglobin complex scavenger receptor CD163 and CD206 are not found to be expressed by foam cells [23](#path5392-bib-0023){ref-type="ref"}, [92](#path5392-bib-0092){ref-type="ref"}. Single‐cell transcriptional analysis of plaque macrophages by Fernandez *et al* [33](#path5392-bib-0033){ref-type="ref"} further revealed the presence of pro‐inflammatory and foamy anti‐inflammatory macrophage subpopulations. The pro‐inflammatory macrophages in human plaques expressed increased levels of activation markers such as HLA‐DRA, CD74, CYBA, LYZ2, AIF1, TLR4 agonist S100A8/A9, MALAT1, JUNB and NFKBIA. The foamy anti‐inflammatory macrophage subset was enriched for the expression of LGALS3 and foam cell‐related transcripts such as APOC1, APOE, CTSB, FABP5 [93](#path5392-bib-0093){ref-type="ref"} and perilipin 2 (PLIN2). PLIN2 expression is induced upon lipid uptake in macrophages and foam cells [94](#path5392-bib-0094){ref-type="ref"}, [95](#path5392-bib-0095){ref-type="ref"}. Moreover, *Plin2*‐deficiency protects *Apoe* ^−/−^ mice from atherosclerosis. The phenotype of the foamy anti‐inflammatory macrophage subset may be comparable with the TREM2^hi^ macrophages found in mouse atherosclerotic plaques. Furthermore, Kim *et al* [29](#path5392-bib-0029){ref-type="ref"} showed that human foamy macrophages were more anti‐inflammatory compared with non‐foamy macrophages in human atherosclerotic plaques, as foamy macrophages expressed significantly less *Il1b*. Studies focusing on other diseases, such as multiple sclerosis and obesity, also provide supporting evidence regarding the translation of the mouse to human foamy macrophage subset phenotype. TREM2 is highly expressed on myelin‐laden foamy macrophages in actively demyelinating multiple sclerosis lesions [96](#path5392-bib-0096){ref-type="ref"}. Moreover, foam cells in multiple sclerosis lesions have a more anti‐inflammatory phenotype [97](#path5392-bib-0097){ref-type="ref"}. CD9^hi^ adipose tissue macrophages of obese patients had higher intracellular lipid content compared with CD9^lo^ adipose tissue macrophages [98](#path5392-bib-0098){ref-type="ref"}. Jaitin *et al* [77](#path5392-bib-0077){ref-type="ref"} identified a lipid‐associated macrophage subset with an enriched transcriptional signature of *Trem2, Lipa, Lpl, Ctsb, Ctsl, Fabp4, Fabp5, Lgals1, Lgals3, Cd9* and *Cd36* in the adipose tissue of obese mice, which could be confirmed in humans. Moreover, protein expression of CD9 was also confirmed in these cells.

Thus, it seems that the murine and human plaques both enclose pro‐inflammatory macrophages, foamy anti‐inflammatory macrophages and resident‐like macrophages. However, future studies are required to draw a more powerful and complete picture of the mouse‐to‐human translation. Such studies should involve direct computational comparisons of the single‐cell macrophage transcriptomes between mice and men.

Limitations of single‐cell studies {#path5392-sec-0008}
==================================

The high technical noise and variability of scRNAseq data are known issues that are larger compared with bulk RNAseq [99](#path5392-bib-0099){ref-type="ref"}, [100](#path5392-bib-0100){ref-type="ref"}. A major fraction of the transcripts is not detected in all cells, resulting in false‐negative read counts, also referred to as dropouts. To improve sequencing depth, previous studies sorted the cells of interest using fluorescence‐activated cell sorting (FACS) before scRNAseq library preparation [29](#path5392-bib-0029){ref-type="ref"}, [34](#path5392-bib-0034){ref-type="ref"}. For generating unbiased and reproducible scRNAseq results, dropouts and low‐quality cells should be identified and excluded during quality control. Variability among different cells can be reduced by using either unique molecular identifiers or RNA spike‐ins, which can be used to normalise the scRNAseq data [101](#path5392-bib-0101){ref-type="ref"}, [102](#path5392-bib-0102){ref-type="ref"}, [103](#path5392-bib-0103){ref-type="ref"}. Numerous methods are available that identify dropout events and impute these missing values, resulting in more accurate scRNAseq analysis [104](#path5392-bib-0104){ref-type="ref"}, [105](#path5392-bib-0105){ref-type="ref"}, [106](#path5392-bib-0106){ref-type="ref"}, [107](#path5392-bib-0107){ref-type="ref"}, [108](#path5392-bib-0108){ref-type="ref"}. The imputation of missing values is based on either gene expression of similar cells or gene‐to‐gene relationships. Tools that were originally designed for bulk RNAseq data may not be suitable for scRNAseq data. New tools have been developed to improve normalisation [109](#path5392-bib-0109){ref-type="ref"}, [110](#path5392-bib-0110){ref-type="ref"}, [111](#path5392-bib-0111){ref-type="ref"}, subpopulation identification and comparison, including cross‐species comparisons [112](#path5392-bib-0112){ref-type="ref"}, differential expression analysis [113](#path5392-bib-0113){ref-type="ref"} and batch effect correction [114](#path5392-bib-0114){ref-type="ref"}, [115](#path5392-bib-0115){ref-type="ref"}. To handle the high dimensional scRNAseq data, dimensionality reduction and feature selection approaches have been created, such as t‐distributed stochastic neighbour embedding [116](#path5392-bib-0116){ref-type="ref"}, uniform manifold approximation and projection [117](#path5392-bib-0117){ref-type="ref"}, and scvis [118](#path5392-bib-0118){ref-type="ref"}. Most of the scRNAseq studies to date sequenced only the 3′ transcriptome, although there are also techniques available that capture either the 5′ or full‐length transcriptome and enable the detection of RNA splicing, RNA editing variants, long non‐coding RNA and circular RNA [119](#path5392-bib-0119){ref-type="ref"}, [120](#path5392-bib-0120){ref-type="ref"}.

Previous work has shown that macrophages are more susceptible than other cell types to becoming damaged during the enzymatic and mechanical dissociation procedures required for scRNAseq, often resulting in an under‐representation of macrophages [121](#path5392-bib-0121){ref-type="ref"}. Moreover, different digestion protocols may favour different cell subsets to survive, resulting in over‐representation of certain populations. To overcome this problem, CIBERSORT has been developed, which estimates the abundance of cell populations based on gene expression data from bulk RNAseq [122](#path5392-bib-0122){ref-type="ref"}. Alternatively, techniques without tissue dissociation, such as spatial transcriptomics, which visualises and determines the transcriptome of tissue sections [123](#path5392-bib-0123){ref-type="ref"}, and the combination of laser capture microscopy and Smart‐seq2 may be an outcome in the confirmation of the current findings [124](#path5392-bib-0124){ref-type="ref"}.

In summary, the application of numerous wet‐laboratory protocols and many different algorithms makes it currently challenging to directly compare different studies with each other. This may also explain differences in identified macrophage subsets in atherosclerosis. Cochain *et al* [28](#path5392-bib-0028){ref-type="ref"} showed that a higher resolution analysis may result in an increased number of macrophage subsets by extracting and re‐analysing the single‐cell transcriptional data from the macrophage clusters. Fortunately, the previous limitations of scRNAseq, such as batch effects, are minimised by the rapid development of new bioinformatics software.

Future perspectives {#path5392-sec-0009}
===================

Here we have discussed three main macrophage populations that have been identified within atherosclerotic plaques. A better understanding of the cell phenotype and function of these populations and their association with disease, clinical features of patients and future events may aid in steering future approaches to limit atherosclerosis complications. Current mouse data may support such progress. For instance, Kim *et al* [29](#path5392-bib-0029){ref-type="ref"} showed that foam cell activity correlates with cell profiles of resolution and plaque regression, whereas inflammatory macrophage activity associates with factors involved in atherosclerosis progression. Linking current mouse studies with upcoming and available human data will be essential for extrapolating model observations to clinical settings. Moreover, expanding datasets in future studies on human atherosclerosis should involve association with clinical data including plaque features (e.g. cellular content, necrotic core, collagen deposition) to better associate specific transcriptomes to clinically relevant parameters. We suggest that ongoing research should further characterise these macrophage subsets. For instance, future CyTOF experiments applying series of macrophage markers described in this review may confirm and further detail the existence of macrophage populations in atherosclerosis of mice and men. In addition, subpopulation‐specific markers can also be applied to isolate these populations by flow‐sorting and subsequent detailed characterisation of cellular phenotypes. Furthermore, single‐cell assay for transposase‐accessible chromatin sequencing (ATAC‐seq) and single‐cell chromatin immunoprecipitation (ChIP‐seq) studies may be used to characterise the epigenomic landscape of macrophage subsets to further unravel their regulatory pathways, such as the epigenetic processes and transcription factors that control them.

Based on these studies, detailed identification of cell populations that are detrimental in disease may be defined, as well as pathways, cytokines or other local inflammatory cues that promote them. Alternatively, reparative pathways dampening plaque worsening may also be identified. These insights will define new therapeutic interventions to control relevant macrophage populations in atherosclerotic disease. To limit off‐target effects of potential therapeutics aimed at such macrophage populations, cell‐specific targeting may be required. Nanomedicine has been applied as therapeutic agents that accurately target macrophages [125](#path5392-bib-0125){ref-type="ref"}. High‐density lipoproteins are natural nanoparticles with an affinity for atherosclerotic plaque macrophages [126](#path5392-bib-0126){ref-type="ref"} that can be applied for the treatment of atherosclerosis [127](#path5392-bib-0127){ref-type="ref"}, [128](#path5392-bib-0128){ref-type="ref"}, for example by loading with relevant drugs to re‐educate lesional macrophages, as has been applied in the cancer field [129](#path5392-bib-0129){ref-type="ref"}, [130](#path5392-bib-0130){ref-type="ref"}.

In conclusion, the development of single‐cell technologies, such as scRNAseq and CyTOF, has made it possible to characterise macrophage and other immune cell subsets in the atherosclerotic plaque in great detail and to compare atherosclerotic settings with those in the healthy aorta. So far, three key macrophage populations (resident‐like, pro‐inflammatory and anti‐inflammatory foamy TREM2^hi^) have been described that exist in the atherosclerotic plaque. Future studies should particularly focus on the translation of mouse atherosclerotic immune cell populations to human pathophysiology and linkage to human disease.
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